LAS VEGAS - TelAve -- As demand for specialized outpatient healthcare continues to rise, companies capable of combining disciplined expansion with strong operational execution are drawing increased attention from investors. Cardiff Lexington Corporation (Stock Symbol O T C Q X: CDIX) is steadily emerging as one of those companies.

Through its wholly owned subsidiary, Nova Ortho and Spine, Cardiff Lexington is building a regional specialty healthcare platform focused on orthopedics, spine surgery, pain management, and related ancillary services throughout Florida and the Southeast. Instead of relying on a single practice or acquisition, the company is executing a long-term strategy designed to create an integrated network of specialty medical facilities positioned to benefit from powerful demographic and healthcare trends.

Over the past year, Cardiff Lexington has strengthened its financial performance while expanding its clinical footprint, increasing surgical capacity, and enhancing its capital markets profile. These accomplishments reflect management's disciplined approach to building a scalable healthcare organization.

Financial Results Continue To Improve

Cardiff Lexington's recent financial performance highlights the progress being made across the organization.

For fiscal 2025, the company reported revenue growth of nearly 40% to approximately $11.5 million while gross profit increased more than 60% year over year. Gross margins remained above 60%, demonstrating management's ability to improve profitability while continuing to invest in expansion.

The company also achieved four consecutive quarters of positive Adjusted EBITDA, an important milestone that reflects improving operating leverage as Nova Ortho and Spine expands its network.

Operational metrics remain encouraging as well. Management recently reported treating approximately 180 patients each month while maintaining collection rates exceeding 95%, underscoring the strength of its revenue cycle management and recurring patient demand.

Together, these results suggest Cardiff Lexington is developing a healthcare platform capable of producing sustainable revenue growth alongside improving operational efficiency.

Expanding Its Surgical Network Across Florida

One of the company's most significant recent milestones came with the announcement that Nova Ortho and Spine has expanded into Tallahassee through the addition of Southeastern Surgery Center, bringing its network to twelve surgical centers.

More on TelAve News

• Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
• Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
• Slotozilla Reports Strong Growth in Q2 2026
• Flexible Plan Investments Names Carl Resnick President
• Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety

The facility immediately expands Nova Ortho's capabilities in minimally invasive spine and pain management procedures while providing the foundation for future open surgical procedures as patient demand continues to grow.

Tallahassee represents an important strategic market. As Florida's capital and one of the state's largest metropolitan areas, it offers access to a substantial patient population while strengthening Nova Ortho's referral network throughout North Florida.

Each additional surgical center expands more than patient access. It enhances physician relationships, increases procedural capacity, improves operational efficiencies, and creates additional recurring healthcare revenue opportunities as the network continues to mature.

The Tallahassee announcement follows several additional expansion initiatives announced during recent months.

Nova Ortho recently opened a new medical office in Stuart, Florida, extending its presence into the rapidly growing Treasure Coast region. The company has also expanded specialty orthopedic and spine services into underserved communities, including Perry, Florida, further demonstrating management's commitment to increasing access to advanced musculoskeletal care throughout the state.

Together, these initiatives illustrate a balanced growth strategy that combines expansion into larger metropolitan markets with opportunities in underserved communities where demand for specialty care remains strong.

Building A Regional Healthcare Platform

While the company's recent expansion announcements have attracted attention, the larger story may be Cardiff Lexington's long-term vision.

Management is assembling an integrated specialty healthcare platform focused on orthopedic care, spine surgery, and pain management—medical specialties supported by favorable long-term demographic trends and consistent patient demand.

Healthcare remains highly fragmented, with many independent physician practices facing rising operating costs, staffing shortages, and increasing administrative complexity. Nova Ortho and Spine's platform is designed to provide physicians with operational support and infrastructure while allowing them to remain focused on patient care.

As additional clinics and surgical centers become integrated into the network, Cardiff Lexington has opportunities to strengthen referral relationships, improve operational efficiency, and increase procedural volume throughout its growing organization.

Strengthening Its Capital Markets Position

Cardiff Lexington has also continued making meaningful progress in the public markets.

The company's recent upgrade to the OTCQX Best Market reflects its commitment to enhanced corporate governance, financial transparency, and higher reporting standards while increasing visibility among both institutional and retail investors.

More on TelAve News

• Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
• No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
• The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
• Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
• FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)

Management has also secured a flexible equity purchase facility that provides additional capital to support future acquisitions and expansion initiatives. Combined with improving operating performance, this financial flexibility provides resources to continue building the company's regional healthcare platform while pursuing additional strategic opportunities.

Why Investors Are Watching CDIX

Cardiff Lexington's investment story is supported by multiple complementary growth drivers.

The company has demonstrated accelerating revenue growth, expanding gross margins, positive Adjusted EBITDA, geographic expansion, and continued investment in clinical infrastructure. At the same time, Nova Ortho and Spine continues growing its regional footprint through new medical offices, additional surgical centers, and expanded physician relationships.

Orthopedic care, spine surgery, and pain management remain among healthcare's most durable specialty markets as an aging population and increasing demand for outpatient procedures continue supporting long-term industry growth.

Rather than relying on a single catalyst, Cardiff Lexington is executing a strategy built on operational discipline, recurring healthcare revenue, regional expansion, and scalable platform development.

The Bottom Line

Cardiff Lexington Corporation continues to execute a growth strategy that is becoming increasingly evident through both its financial performance and operational expansion.

With twelve surgical centers, expanding specialty medical services, improving profitability, a stronger capital markets profile, and a clear focus on building an integrated healthcare platform, the company has established a foundation for continued growth.

While all emerging healthcare companies face execution risks, Cardiff Lexington has consistently demonstrated measurable progress across many of the operational milestones investors monitor most closely. Revenue growth, improving margins, disciplined geographic expansion, and continued investment in healthcare infrastructure highlight management's commitment to creating long-term shareholder value.

As Nova Ortho and Spine continues expanding throughout Florida and the Southeast, Cardiff Lexington appears well positioned to capitalize on increasing demand for specialized orthopedic, spine, and pain management services. For investors seeking exposure to a rapidly growing specialty healthcare platform with improving fundamentals and an expanding regional footprint, Cardiff Lexington Corporation (Stock Symbol: CDIX) remains a company worthy of close attention.

For more information on CDIX visit: https://cardifflexington.com/

Media Contact:
Company Name: Cardiff Lexington Corporation (Stock Symbol: CDIX)
Contact: Alex Cunningham, CEO
Email:  investorsrelations@cardifflexington.com
Phone: (800) 628-2100 ext. 705
Country: United States
Website:  https://cardifflexington.com/

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website